EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 3.0

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study

Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin und 6 weitere

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.479 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Yoon Seok Choi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Bortezomib, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.Materials and Methods Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.

Results

Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.

Conclusion

This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsLymphoma, T-Cell, CutaneousNeoplasm Recurrence, LocalSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment OutcomeMaintenance ChemotherapyDrug Resistance, NeoplasmInduction Chemotherapy

Stichwörter der Autor:innen

BortezomibCutaneous T-cell lymphomaDexamethasoneRelapsed/refractorySafety profileTreatment efficacy

Substanzen

BortezomibDexamethasone

Autor:innen und Institutionen

  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
  • Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital,…

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Choi, Y. S., Shim, J., Kang, K. W., Yoon, S. E., Hong, J. S., Lim, S. N., Yhim, H. Y., Kwon, J. H., Lee, G. W., Yang, D. H., Oh, S. Y., Shin, H. J., Eom, H. S., Yoon, D. H., Lee, H. G., Jeong, S. H., Kim, W. S., & Kim, S. J. (2025). Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.479

Vancouver

Choi YS, Shim J, Kang KW, Yoon SE, Hong JS, Lim SN, et al. Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.479

BibTeX
@article{Choi2025,
  author = {Choi, Yoon Seok and Shim, Joonho and Kang, Ka-Won and Yoon, Sang Eun and Hong, Jun Sik and Lim, Sung Nam and Yhim, Ho-Young and Kwon, Jung Hye and Lee, Gyeong-Won and Yang, Deok-Hwan and Oh, Sung Yong and Shin, Ho-Jin and Eom, Hyeon-Seok and Yoon, Dok Hyun and Lee, Hong Ghi and Jeong, Seong Hyun and Kim, Won Seog and Kim, Seok Jin},
  title = {Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.479}
}
Kostenlos starten →